Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Basic Science: Safety, Tolerability, Efficacy of CLP
Interventions
Cross-Linked Polyelectrolyte (CLP)
Drug
Lead sponsor
Sorbent Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Kalamazoo, Michigan
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Recruiting No phase listed Observational Accepts healthy volunteers

fMRI and IVCM Cornea Microscopy of CXL in Keratoconus

NCT04439552
Conditions
Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Enrolling by invitation No phase listed Observational

MDR Vivacit-E Elevated Study

NCT07150221
Conditions
Osteoarthritis (OA) of the Hip, Avascular Necrosis of Bone of Hip, Protrusio Acetabuli, Traumatic Arthropathy-Hip, Slipped Capital Femoral Epiphyses, Fused Hip, Fracture of Pelvis, Diastrophic Variant
Interventions
Vivacit-E Elevated Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
South Bend, Indiana
Conditions
Heart Failure
Interventions
CLP, placebo
Drug
Lead sponsor
Sorbent Therapeutics
Industry
Eligibility
21 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tustin, California
Completed Not applicable Interventional

Vivacit-E Post-market Follow-up Study

NCT03226808
Conditions
Osteoarthritis, Avascular Necrosis of Bone of Hip, Post-traumatic; Arthrosis, Congenital Hip Dysplasia
Interventions
Vivacit-E Liner
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 60 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
5
States / cities
Parker, Colorado • Chapel Hill, North Carolina • Charlotte, North Carolina + 2 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

McNeel Eye Center Corneal Crosslinking Study

NCT02921009
Conditions
Keratoconus
Interventions
Crosslinking using UV light of two different fluence rates
Device
Lead sponsor
McNeel Eye Center
Industry
Eligibility
15 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boise, Idaho
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, Epi-Off
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
10 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Keratoconus, Post-Refractive Ectasia
Interventions
Riboflavin, UVX light
Drug · Device
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Osteoarthritis, Knee
Interventions
Cingal, Triamcinolone Hexacetonide (TH), Placebo
Drug
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Chandler, Arizona • Tucson, Arizona • Anaheim, California + 21 more
Conditions
Arthroplasty, Replacement, Knee
Interventions
knee arthroplasty, standard polyethylene, knee arthroplasty, XLP polyethylene
Device
Lead sponsor
Chapel Hill Orthopedics Surgery & Sports Medicine
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid

NCT04315415
Conditions
Vocal Fold Palsy, Vocal Cord Paralysis, Vocal Cord Atrophy
Interventions
Silk Voice
Device
Lead sponsor
Sofregen Medical, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study

NCT04754087
Conditions
Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip
Interventions
Vivacit-E and Longevity (HXLPE) Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2033
U.S. locations
6
States / cities
Denver, Colorado • South Bend, Indiana • Durham, North Carolina + 3 more
Conditions
Hernia, Ventral, Intestinal Fistula, Fibromatosis, Abdominal
Interventions
Abdominal wall reconstruction with Strattice, Assess pain intensity at last office visit preoperatively, Assess pain interference at last office visit preoperatively, Assess physical functioning at last office visit preoperatively, Assess patient quality of life at last office visit preoperatively, Assess patient pain intensity postoperatively, Assess pain interference postoperatively, Assess physical functioning postoperatively, Assess quality of life postoperatively, Assess hernia recurrence at 30 days postoperatively, Assess bulge at 30 days postoperatively, Assess Surgical Site Occurrences at 30 days postoperatively, Assess hernia recurrence at 1 year postoperatively, Assess bulge at 1 year postoperatively, Assess Surgical Site Occurrences at 1 year postoperatively, Assess overall complications at 30 days postoperatively, Assess overall complications at 1 year postoperatively, Abdominal wall reconstruction with XenMatrix, Strattice, XenMatrix
Procedure · Other · Device
Lead sponsor
Jeffrey Janis
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Unstable Corneas
Interventions
Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
Drug · Device
Lead sponsor
Crowd Health Research, LTD
Other
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
16
States / cities
Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
Not listed Phase 2 Interventional Accepts healthy volunteers

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298
Conditions
Keratoconus, Ectasia, Corneal Ectasia
Interventions
UV-X Light, Riboflavin
Device · Drug
Lead sponsor
Mercy Center for Corrective Eye Surgery
Other
Eligibility
14 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
McHenry, Illinois
Conditions
Cardiovascular Disease
Interventions
Hemolink (hemoglobin raffimer IV solution)
Drug
Lead sponsor
Hemosol
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 14 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Marathon and Enduron Polyethylene at Long-Term Follow-up

NCT02508428
Conditions
Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
Hip Replacement with crosslinked Marathon polyethylene, Hip Replacement with noncrosslinked Enduron polyethylene
Device
Lead sponsor
Anderson Orthopaedic Research Institute
Other
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2017
U.S. locations
1
States / cities
Alexandria, Virginia
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Corneal Crosslinking in Keratoconus and Corneal Ectasia

NCT00679666
Conditions
Progressive Keratoconus, Corneal Ectasia
Interventions
Riboflavin, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Columbus, Ohio • Dublin, Ohio
Conditions
Keratoconus
Interventions
Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Dry Eye Disease (DED)
Interventions
Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Conditions
Keratoconus, Cornea Ectasia
Interventions
Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.
Combination Product
Lead sponsor
Arbor Center for Eye Care
Other
Eligibility
12 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orland Park, Illinois
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more